CryOSA is developing a medical device that employs targeted airway pressure modulation to treat obstructive sleep apnea. This non-invasive approach enhances patient compliance and minimizes the risk of health complications associated with traditional CPAP therapy.
Funding
$29.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCSBFounders
Product
Problem
Obstructive sleep apnea (OSA) affects millions worldwide, and current treatments like CPAP are often poorly tolerated, while surgical alternatives can be painful and invasive. This leads to suboptimal adherence and continued health risks for many patients.
Solution
Cryosa is developing a medical device that utilizes targeted airway pressure modulation to treat moderate to severe obstructive sleep apnea (OSA). This approach aims to provide a mask-free, hose-free, and implant-free solution, enhancing patient compliance and minimizing complications associated with traditional therapies. By delivering a non-invasive treatment option, Cryosa seeks to improve sleep quality and overall health outcomes for individuals suffering from OSA. The technology is currently under investigation and not yet approved for use in the US or Europe.
Target Audience
The primary target audience includes individuals with moderate to severe obstructive sleep apnea (OSA) who are seeking alternative treatment options to traditional CPAP therapy or invasive surgical procedures.
Features
- Targeted airway pressure modulation for OSA treatment
- Non-invasive approach, eliminating the need for masks, hoses, or implants